Senti Biosciences, Inc.

SNTI

NASDAQ

Healthcare

Biotechnology

South San Francisco, CA, US34 employeessentibio.com

$0.87

+0.03(3.56%)

Mkt Cap $23M

$0.77

$5.00

52-Week Range

At a Glance

AI-generated

Senti Biosciences, Inc.

Revenue breakdown: Reportable Segment (100%).

8-K

Senti Biosciences, Inc. announced plans for a holding company reorganization, which would convert existing common stock into equivalent shares of a new parent entity, Senti Biosciences Holdings, Inc., expected to be effective by April 16, 2026.

$23M

Market Cap

—

Revenue

-$48M

Net Income

Employees34

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($22.0K)

Activity

What Changed Recently

Financial Results

Mar 26, 2026

of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as

Material Agreement

Mar 18, 2026

Entry into a Material Definitive Agreement. Lease Amendment On March 17, 2026, Senti Biosciences, Inc. (the “Company”) entered into a First Amendment to Lease (

Other Event

Mar 31, 2026

Other Events On April 1, 2026, Senti Biosciences, Inc. (the “Company”) announced plans to implement a holding company reorganization (the “Holding Company Reorg

Peer Companies

Company	Price	Change	Market Cap	P/E
IPSCCentury Therapeutics, Inc...	$2.15	-2.05%	$186M	-21.4
KPTIKaryopharm Therapeutics I...	$5.88	+1.03%	$50M	-0.6
ALGSAligos Therapeutics, Inc.	$7.86	+1.55%	$49M	-2.9
XFORX4 Pharmaceuticals, Inc.	$4.22	-2.99%	$48M	-5.7
COEPCoeptis Therapeutics Hold...	$11.94	+5.85%	$42M	-3.9
CVMCEL-SCI Corporation	$3.49	+1.75%	$24M	—
BRNSBarinthus Biotherapeutics...	$0.57	+5.72%	$23M	-0.4
CUECue Biopharma, Inc.	$0.18	-11.20%	$14M	-1.1

Analyst View

Company Profile

CIK0001854270

ISINUS81726A2096

CUSIP81726A100

Phone(650) 382-3281

Address2 Corporate Drive, South San Francisco, CA, 94080, US

SEC EDGAR